• Muhammad Nadeem Ahsan, Muhammad Sohaib Asghar, Sadia Iqbal, Haris Alvi, Mohammed Akram, Basmah Fayyaz, Syeda Ghazala Irshad, Irfan Ullah, Sarosh Alvi, and Zohaib Yousaf.
• Department of Nephrology, Dow University of Health Sciences-Ojha Campus, Karachi, Pakistan.
• Medicine (Baltimore). 2023 Feb 10; 102 (6): e32919e32919.

AbstractThe frequency of acute kidney injury (AKI) in COVID-19 patients can be varied and related to worse outcomes in the disease population. AKI is common among hospitalized patients with COVID-19, particularly the ones needing critical care. This study was conducted in order to determine the outcomes of hospitalized patients with prolonged hospital stays who suffered from COVID-19 associated AKI. It was conducted as a multi-centered, retrospective, cohort study, and including all patients who were diagnosed on COVID-19 PCR. End-stage renal disease patients on hemodialysis were excluded. The cohort included 1069 patients, with 68% males, mean age of 56.21 years, and majority within 50 to 75 years age group (60%). Mean disease onset was 14.43 ± 7.44 days and hospital stay was 7.01 ± 5.78 days. About 62% of patients stayed in intensive care and 18% of them were on invasive ventilation. The mortality rate was 27%. Frequency of AKI was 42%, around 14% of them were resolving during hospital stay and other 28% worsened. The mortality rate was significantly higher with AKI (OR: 4.7, P < .001). Alongside AKI, concomitant liver dysfunction was also significantly contributing to mortality (OR: 2.5), apart from ICU stay (OR: 2.9), invasive ventilation (OR: 9.2), and renal replacement therapy (OR: 2.4). Certain laboratory markers were associated with AKI throughout in-hospital stay.Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.

41 keywords...

hide…